About Grace Therapeutics, Inc.
https://www.acastipharma.comGrace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage.
CEO
Prashant Kohli
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-07-10 | Reverse | 1:6 |
| 2021-08-31 | Reverse | 1:8 |
ETFs Holding This Stock
Summary
Showing Top 1 of 10
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
NANTAHALA CAPITAL MANAGEMENT, LLC
Shares:1.18M
Value:$4.29M
AIGH CAPITAL MANAGEMENT LLC
Shares:907.22K
Value:$3.3M
BANK OF AMERICA CORP /DE/
Shares:494.7K
Value:$1.8M
Summary
Showing Top 3 of 21
About Grace Therapeutics, Inc.
https://www.acastipharma.comGrace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2026 | $0 | $2.53M ▼ | $-938K ▲ | 0% | $-0.06 ▲ | $-938K ▲ |
| Q1-2026 | $0 | $3.09M ▼ | $-3.36M ▼ | 0% | $-0.21 ▼ | $-3.09M ▼ |
| Q4-2025 | $0 | $3.18M ▼ | $636K ▲ | 0% | $0.05 ▲ | $-380K ▲ |
| Q3-2025 | $0 | $3.7M ▼ | $-4.16M ▼ | 0% | $-0.36 ▼ | $-3.7M ▲ |
| Q2-2025 | $0 | $4.83M | $-3.43M | 0% | $-0.3 | $-4.83M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2026 | $16.86M ▼ | $66.58M ▼ | $3.76M ▼ | $62.82M ▼ |
| Q1-2026 | $20M ▼ | $69.81M ▼ | $6.25M ▲ | $63.55M ▼ |
| Q4-2025 | $22.13M ▲ | $71.99M ▲ | $5.38M ▼ | $66.61M ▲ |
| Q3-2025 | $11.05M ▼ | $61.22M ▼ | $9.09M ▼ | $52.14M ▼ |
| Q2-2025 | $15.17M | $65.35M | $9.21M | $56.13M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2026 | $-938K ▲ | $-3.15M ▼ | $0 | $-769.85 ▲ | $-3.14M ▼ | $-3.15M ▼ |
| Q1-2026 | $-3.36M ▼ | $-1.8M ▲ | $0 | $-327K ▼ | $-2.13M ▼ | $-1.8M ▲ |
| Q4-2025 | $636K ▲ | $-2.95M ▲ | $0 ▼ | $14.03M ▲ | $11.08M ▲ | $-2.95M ▲ |
| Q3-2025 | $-4.16M ▼ | $-4.12M ▲ | $15K ▲ | $0 | $-4.1M ▲ | $-4.12M ▲ |
| Q2-2025 | $-3.43M | $-4.24M | $0 | $0 | $-4.24M | $-4.24M |
CEO
Prashant Kohli
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-07-10 | Reverse | 1:6 |
| 2021-08-31 | Reverse | 1:8 |
ETFs Holding This Stock
Summary
Showing Top 1 of 10
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
NANTAHALA CAPITAL MANAGEMENT, LLC
Shares:1.18M
Value:$4.29M
AIGH CAPITAL MANAGEMENT LLC
Shares:907.22K
Value:$3.3M
BANK OF AMERICA CORP /DE/
Shares:494.7K
Value:$1.8M
Summary
Showing Top 3 of 21